

Renal neoplasias developing in ends stage kidney disease secondary to therapeutic modalities

PhD thesis

Norbert Sule, M.D.

PhD School Director: Prof. Judit Nagy

Program director: Prof. Laszlo Pajor

**Department of Pathology
University of Pecs Medical School
2006**

TABLE OF CONTENT

Abbreviation list	21
Summary of new results	22
Introduction	23
Materials and Methods	25
Results	25
Discussion	26
Summary	32
Publication list used for the PhD thesis	33
Publication List	34
List of Presentation	37
References	40

ABBREVIATION LIST

ESRD: end stage renal disease

RCC: renal cell carcinoma

EMA: epithelial membrane antigen

HMWCK: high molecular weight cytokeratin

KSC: kidney specific cadherin

CaOx: Calcium oxalate

CaOx +: Calcium oxalate positive

CaOx -: Calcium oxalate negative

PAS: Periodic Acid-Schiff

ACKD: Acquired Cystic Kidney Disease

SUMMARY OF NEW RESULTS:

1. The Ph.D theses discusses renal cell carcinomas developing in the acquired cystic kidney disaes secondary to dialysis treatment.
2. The Ph.D theses describes a new phenotypic variant of renal cell carcinoma (called oxalate type by the authors) associated with intratumoral Calcium Oxalate depositon. The study suggests the need for a new classification system.
3. Immunohistochemical characterizationi of the new „oxalate type” renal cell carcinoma.
4. Discussion of role of the new renal cell carcinoma phenotype and its differentiation in the CaOx deposition .
5. The first case description of a carcinoasarcoma developed in a transplant kidney.

INTRODUCTION:

For patients suffering from end stage renal disease the only therapeutic option is dialysis until a kidney becomes available for transplantation. The prevalence of neoplastic disease affecting the urinary tract in both the dialysed and the transplanted patient population is increased.

Acquired cystic kidney disease (ACKD) is characterized by small cysts randomly distributed throughout the renal cortex and medulla of patients with end-stage renal disease (ESRD) unrelated to polycystic kidney disease (Dunnill, et al., 1977; Grantham, 1991; Ishikawa, 1991; Ishikawa, et al., 1990; Matson and Cohen, 1990; Truong, et al., 1995). Both the prevalence and severity of ACKD increase with the duration of ESRD and ACKD has been reported in almost all patients after more than 10 years of dialysis (Ishikawa, 1991; Matson and Cohen, 1990).

Renal neoplasm is noted in 4.2-5.8% of ESRD patients, reflecting a marked increase in its incidence compared with the general population (Hughson, et al., 1986; Ishikawa, et al., 1990; Matson and Cohen, 1990; Truong, et al., 1995). Although these neoplasms were rarely reported in a shrunken kidney without cystic changes, the vast majority of them develop from the background of ACKD (Hughson, et al., 1980; Ishikawa, et al., 1990; Truong, et al., 1995). The involvement is usually bilateral/multifocal and displays a spectrum of closely associated lesions including simple cysts, cyst lined by hyperplastic epithelium with or without atypia, adenoma, and renal cell carcinoma (RCC) with or without metastasis (Dunnill, et al., 1977; Hughson, et al., 1986). Some previous studies have suggested that the histologic types of RCCs in this context are similar to those in the general population but with overrepresentation of the papillary RCC (Dunnill, et al., 1977; Hughson, et al., 1996; Ishikawa and Kovacs, 1993; Truong, et al., 1995). In fact, the histologic features of ACKD-associated RCCs are not well studied and

many of these tumors do not fit in any categories in the current classification of renal neoplasms (Denton, et al., 2002; Tickoo, et al., 2003). One of the distinctive features of ACKD-associated RCCs is intratumoral deposition of calcium oxalate (CaOx), which was previously reported in four cases and briefly mentioned in a recent abstract (Denton, et al., 2002; Tickoo, et al., 2003). This feature, to the best of our knowledge, has not been described in RCCs in the general population. Although this finding seems unique for ACKD-associated renal neoplasms, many pertinent features including its frequency, pathogenesis and biologic implications, and the histologic type of the involved RCCs are not known.

For patient suffering from end stage renal disease the transplantation is the ultimate therapeutic solution. As a result of the increasing number of transplant centers and the use of immunosuppressive therapy, the patients' life expectancy is markedly increased and the quality of life dramatically improved. Besides the infection and graft versus host disease secondary to the immunosuppressive treatment the increased incidence of neoplastic diseases in post-transplant patients is a major concern. Geographic difference can be observed in the prevalence of malignancies (USA: 6%, Europe: 1-9%. Australia: 18,3%). After kidney transplantation Kaposi's sarcoma, non-Hodgkin's lymphomas, and non-melanoma skin cancers represents the most common secondary neoplasms (more than 20-fold increased than in the general population), the increase of genito-urinary (G-U) malignancies is also substantial (15-fold increase) (Kasiske, et al., 2004; Samhan, et al., 2005). The incidence of G-U tumors varies between 0.64-1.67%. Since the incidence, type and other characteristics of post-transplant malignancies varies in different geographic regions, many mechanism can play role in the etiology such as: (1) defect in immune surveillance mechanism, (2) increased sensitivity for oncogenic virus infection, (3) lymphoproliferation affecting immunologic feed back mechanism, (4) uremia as a predisposing condition. There are three distinct type of post-transplant renal neoplasms. The

tumor can develop in the (a.) donor's or (b.) recipient's kidney prior the transplantation, which emphasises the importance of pretransplant renal ultrasonograph examination and cystoscopy. The third group is the de novo malignancies, which can develop in the patient's own (90%) or in the transplanted kidney (10%) (Penn, 1998). The prevalence of de novo renal cell carcinomas is higher (4.1-4.6%), than of the sporadic cases. It is important to mention the unusually high percentage of renal pelvis tumors (15%) among de novo carcinomas (Penn, 1998).

In my studies I characterized the morphological appearance and immunological expression profile of the renal neoplasias developing in ends stage kidney disease secondary to therapeutic modalities with special attention to those neoplasms with calcium oxalate deposition. Beside reviewing the literature I also first describe a rare type of neoplasm presented in a transplanted kidney.

MATERIALS AND METHODS:

I. Neoplasms developing in the native kidneys of the dialysis treated patients

The study features 30 end-stage renal disease (ESRD)-associated RCCs identified within a 13-year period, including eight with CaOx deposition, were analyzed. Pathologic and clinical features of CaOx positive (+) and negative (-) RCCs were evaluated and compared.

II. Neoplasm developing in renal transplant patients

The study describes a renal carcinosarcoma developed in an allograft kidney and reviews neoplastic diseases arising in transplant patients with special attention to genito-urinary neoplasms.

RESULTS:

I. Neoplasms developing in the native kidneys of the dialysis treated patients

The CaOx+ RCCs showed higher tendency for bilaterality and multifocality. Seven tumors displayed distinctive morphologic features characterized by tumor cells with ill-defined cell membrane, abundant granular eosinophilic cytoplasm, large nuclei, and prominent nucleoli. One tumor was of clear cell type. Regardless of histologic type, all tumors displayed a proximal tubular differentiation. No significant difference was noted for tumors' stage, proliferation and apoptosis rate between the CaOx+ and CaOx- RCCs.

II. Neoplasm developing in renal transplant patients

A multifocal urothelial carcinosarcoma of a transplanted kidney in a 49-year-old woman is described. The performed immunohistochemical characterization revealed the CK positivity of both the epithelial and the sarcomatoid areas. Vimentin expression of the sarcomatoid component was also noted. Genomic analysis of the extracted nuclei of all the neoplastic cells showed uniformly XY genotype proving the transplant origin of the tumor. The occurrence of the carcinosarcoma is extremely rare, our case represents the first published case in the english literature.

DISCUSSION:

I. Neoplasms developing in the native kidneys of the dialysis treated patients

This comprehensive evaluation of CaOx+ RCCs in ESRD patients shows that they are not rare and indeed accounted for 8/30 (27%) of all RCCs developing from this background. This high incidence is somewhat surprising because only 19 CaOx + RCCs were previously reported (Dry and Renshaw, 1998; Rioux-Leclercq and Epstein, 2003) and this type of RCC was not mentioned in any large studies on ESRD-associated renal neoplasms (Denton, et al., 2002; Doublet, et al., 1997; Dunnill, et al., 1977; Hughson, et al., 1986; Hughson, et al., 1980; Hughson, et al., 1996; Ikeda, et al., 2002; Ishikawa, et al., 1990; MacDougall, et al., 1987; Miller, et al., 1989; Takebayashi, et al., 2000; Truong, et al., 1995). Since CaOx crystals are colorless but highly visible under polarized light in the hematoxylin-eosin stain and were dissolved during the periodic acid-Schiff or Mason's trichrome stains, which are frequently used to evaluate ESRD-associated renal parenchyma changes, they may be overlooked unless the deposition is extensive or polarized light is routinely used. Although the high incidence in our study may be related to the fact that CaOx was specifically sought for in all RCCs, extensive deposition involving more than 75% of tumor areas were noted in 4/8 (50%) of these tumors. A recent abstract documented that 15 out of 43 (35%) RCCs in ESRD patients contain CaOx, supporting our observation that these tumors are not rare (Tickoo, et al., 2003).

Our study together with previous reports (Dry and Renshaw, 1998; Rioux-Leclercq and Epstein, 2003; Tickoo, et al., 2003) indicates that intra-tumoral CaOx deposition is a unique features of ESRD-associated renal neoplasms including RCCs, since, to the best of our knowledge, it has never been described in renal neoplasms in the general

population and, indeed, was not observed in any of the 346 RCCs unrelated to ESRD during the studied period. Previous studies by Dry *et al*, Rioux-Leclercq *et al*, and Tickoo *et al* suggested that intra-tumoral CaOx deposition is associated with a distinctive morphologic profile (Dry and Renshaw, 1998; Rioux-Leclercq and Epstein, 2003; Tickoo, et al., 2003). The current study confirms and expands this observation, i.e., this profile is observed in almost all RCCs with CaOx deposition but only rarely seen in RCCs without it. Furthermore, this profile does not fit neatly into the current histological classification of renal tumors (Storkel, et al., 1997).

Almost all CaOx+ RCCs were composed entirely or almost entirely of tumor cells with cuboidal abundant eosinophilic granular cytoplasm, focal but prominent cytoplasmic vacuolization, ill defined cell membrane, and a Furhman's nuclear grade 3. These tumors, however, have diverse growth patterns including predominantly papillary, tubulopapillary, or solid/cribriform types. Although the amount of intra-tumoral CaOx is variable, the deposition is extensive and accounts for more than 75% of tumor areas in at least 50% of our cases. Indeed, tumor calcification was obvious on imaging studies of two of these cases. The CaOx deposition was not associated with any distinctive tissue reaction such as necrosis, fibrosis or inflammation only one case showed multinucleated giant cell reaction. This morphologic profile correlates well with intra-tumoral CaOx since it is noted in seven out of eight CaOx+ RCCs in the current study, all five previously reported CaOx+ RCCs, and all 15 CaOx+ RCCs in a recent abstract that included 43 ESRD-associated RCCs (Dry and Renshaw, 1998; Rioux-Leclercq and Epstein, 2003; Tickoo, et al., 2003). On the other hand, this morphologic profile was found in only 1/18 CaOx- RCCs in the current study and none of the 28 CaOx- RCCs in another study (Dry and Renshaw, 1998; Rioux-Leclercq and Epstein, 2003; Tickoo, et al., 2003). This phenotype, however, is not pathognomic for intra-tumoral CaOx, since one RCC

with extensive CaOx deposition in our study displays typical clear cell features.

The biologic significance of CaOx+ RCC as a distinctive subset of ESRD-associated RCC is not clear. Although bilaterality and multifocality is well known for ESRD-associated RCCs (Ishikawa, et al., 1990; Matson and Cohen, 1990; Truong, et al., 1995), we found that these features are significantly more frequent for the CaOx+ RCCs than for its CaOx- counterpart (40 vs. 0% for bilaterality and 57 vs 11% for multifocality in the current study. This observation suggests that CaOx deposition, which is known to be quite frequent and often extensive in kidneys with ESRD, may promote tumor development or, alternatively, the genetic changes that predispose to CaOx deposition also promote malignant transformation.

The durations from dialysis to RCCs in our cases were 8-11 years (mean 9.2 years). This is significantly longer than the mean duration of 5 year reported by Houghson *et al* for ACKD-associated RCCs (Hughson, et al., 1986; Hughson, et al., 1980; Hughson, et al., 1996), regardless of histologic subtype. This difference suggests that the increased bilaterality and multifocality of CaOx+ RCCs may be at least in part related to the duration of dialysis. On the other hand, we have noted that CaOx deposition was always significantly more in CaOx+ RCCs than in the adjacent kidney tissue but the renal tissue deposition of CaOx was not different between those with CaOx+ RCCs and those with CaOx- RCC. These observations suggest that CaOx deposition within the tumor itself may be related to their behavior. Although the majority of ESRD-associated RCCs develop from the background of ACKD, those without associated ACKD have been noted and they account for 9-25% of all ESRD-associated RCCs (Denton, et al., 2002; Tickoo, et al., 2003). In contrast, all CaOx+ RCCs (eight in the current study, five previously reported, and 15 in a recent abstract) are associated with ACKD (Dry and Renshaw, 1998; Rioux-Leclercq and Epstein, 2003; Tickoo, et al., 2003). These observations suggest some

pathogenetic links among tumor bilaterality/ multifocality, renal cyst formation, renal parenchymal CaOx deposition, and intra-tumoral CaOx deposition. Regardless of the pathogenetic implication, our findings imply that the diagnosis of CaOx+ RCC should entail appropriate clinical follow-up for progressive renal cystic change and renal tumors of the contralateral kidneys.

Why CaOx is deposited in only some ESRD-associated RCCs, but not RCC in general, is not clear. Our study suggests at least two responsible factors, i.e., increased serum level of oxalate and a specific cell phenotype that can promote oxalate deposition. Since kidney is the only organ through which oxalate is eliminated, increased serum level of oxalate is expected along with chronic renal failure regardless of etiology (Salyer and Keren, 1973). It is estimated that serum oxalate level starts to increase when glomerular filtration rate is less than 25ml/ minute (Morgan, et al., 1987). Since dialysis can only remove a fraction of the daily oxalate intake, this positive balance is even worse in ESRD patients and the serum level as well as the body burden of oxalate in these patients is progressively increased (Hoppe, et al., 1999; Worcester, et al., 1994). In physiologic condition, oxalate is freely filtered through the glomerular capillaries and undergoes bi-directional transport through the proximal tubules resulting in increased concentration in the tubular lumen, whereas other portions of the nephron do not participate in handling of oxalate (Hatch and Freel, 2003). Our study indicates that the immunoprofile of the CaOx+ RCCs is quite uniform with pronounced expression of markers for proximal tubular differentiation including the RCC marker and CD10 and absent or weak expression of the markers for distal portion of the nephron such as KSP, HMWCK, or EMA. These observations suggest that proximal tubular differentiation may play a crucial role in promoting intra-tumoral CaOx deposition. We also propose that it is the proximal differentiation, rather than light microscopic phenotype, that is important for CaOx deposition since the

only CaOx+ clear cell RCC known to us also displayed strong proximal differentiation, like those with the “oxalate” phenotype. In contrast, all CaOx- RCCs in our study showed predominantly distal nephron differentiation, even though several of them are of clear cell or papillary types, which are known to derive from proximal tubules in the sporadic RCC (Kim and Kim, 2002; McGregor, et al., 2001). Our study also demonstrated that CaOx may deposit in adenomas, cysts, or dilated tubules, but only in those with an immunoprofile of proximal tubular differentiation, further implicating its role in renal CaOx deposition. Additional factors may be involved in CaOx deposition. Several molecules are known to inhibit CaOx crystal formation in physiologic condition, including nephrocalcin, osteonectin, mannan-binding lectin associated plasma protein, and FK506-binding protein, some of which are immunolocalized to renal proximal tubules (Ikeda, et al., 2002). It is possible that lower levels of these molecules may promote CaOx deposition. Although this hypothesis has not been tested, at least one of these molecules, i.e., nephrocalcin was identified in RCCs and shown to decrease in ESRD-associated RCCs (Michaels, et al., 1998). Whether this decrease is limited to the CaOx+ tumors in this context is not known.

CaOx is known to induce significant changes in cultured tubular cells. It may be mitogenic at lower concentration but may cause cell necrosis or apoptosis at higher concentration (Koul, et al., 1994; Scheid, et al., 1996) . CaOx can induce intracellular formation of reactive oxygen species and inhibit several cytosolic enzymes, which may account for its cytotoxic effects (Koul, et al., 1994; Scheid, et al., 1996). CaOx is the major factor in renal tissue injury in renal oxalosis, a condition characterized by renal tissue deposition of CaOx. In the context of ESRD, CaOx was thought to promote cyst and tumor formation through both mechanical obstructions of renal tubules and regulation of tubular cell cycles (Hughson, et al., 1986; Ishikawa, 1991; Lieske, et al., 1992; Truong, et al., 1995). What impact

that intra-tumoral CaOx has on tumor cells, however, is not clear. In the current study, we did not observe in the majority of cases (7/8) any specific tissue reaction in the tumor tissue around the CaOx crystals, only one case showed multinucleated giant cell reaction. Furthermore, the rates of tumor cell proliferation and apoptosis of the CaOx+ RCCs as determined by Ki 67, a specific cell proliferation marker, and *in situ* end-labeling of fragmented DNA, respectively, were widely variable among CaOx+ RCCs but were not significantly different from those of CaOx- RCCs. These features suggest that CaOx deposition may not have any significant impact on tumor cell kinetics.

The behavior of ESRD-associated RCCs, especially those develop in the context of ACKD, is well known. Compared to sporadic RCCs, these tumors are usually of lower grades, lower stages, with a lower metastatic rate and a better survival (Truong, et al., 1995). However, the behavior of different histologic subtypes of RCCs, including the CaOx+ ones, within the broad category of ESRD-associated RCC is not known. Although the CaOx+ RCCs displayed a higher nuclear grade than the CaOx- RCCs, this study suggests that in the context of ESRD, they have the same behavior since no significant difference was noted in these two groups for the tumors' stage, proliferation rate, and apoptotic rate, and the patients' survival. Nevertheless, this suggestion needs to be corroborated in further studies with more cases

II. Neoplasm developing in renal transplant patients

The transplantation provides a better quality of life for the patients if compared to dialysis. The risk of neoplastic diseases is increased after transplantation due to the immunosuppressive therapy. This increased risk, though it is still present, is less prominent if we compare it to the dialysis treated patients.

After transplantaton the majority of renal neoplastic proliferations develop in the native kidney, a small proportion

of post-transplant malignancies can also arise in the donor organs. The majority of these neoplasms are renal cell carcinoma, but the relative proportion of urothelial carcinoma of the renal pelvis is increased (15%) (Penn, 1995) compared to the sporadic cases (8-10 %). Of course, most of these tumors are urothelial carcinoma, but previously in transplanted kidney not reported rare types of cancer can occur in this location.

SUMMARY

Renal neoplasm is noted in 4.2-5.8% of ESRD patients, reflecting a marked increase in its incidence compared with the general population. In summary, CaOx+ RCCs accounts for a significant portion of all ESRD-associated RCCs. Almost all of these RCCs display a distinctive morphologic profile, which does not fit the current histologic classification of RCC. These RCCs seem to have the same relatively good prognosis shared by other ESRD-associated RCCs.

The transplantation provides a better quality of life for the patients if compared to dialysis. The risk of neoplastic diseases is increased after transplantation due to the immunosuppressive therapy.

Both dialyzed and transplanted patients should be monitored for the development of malignancy in native kidneys, the allograft and elsewhere.

**FELHASZNÁLT SAJÁT PUBLIKÁCIÓK/
PUBLICATION LIST USED FOR THE PHD THESIS**

1. **Norbert Sule, M.D.**, Ulkem Yakupoglu, M.D., Steven S. Shen, M.D., Ph.D., Bhuvaneswari Krishnan, M.D., Guang Yang, M.D., Ph.D., Seth Lerner, M.D., and Luan D. Truong, M.D.

Calcium Oxalate Deposition in Renal Cell Carcinoma Associated with Acquired Cystic Kidney Disease. A Comprehensive Study.

Am J Surg Pathol. 2005 Apr;29(4):443-51.

impact factor: 4.5

2. István Buzogány, Fariborz Bagheri, **Norbert Süle**, Tamás Magyarlaki, Károly Kalmár-Nagy, László Farkas, Gábor Pajor
Association between Carcinosarcoma and the Transplanted Kidney

Anticancer Research Jan-Feb 2006, volume 26, issue 1B, pp. 751-754

impact factor: 1.395

PUBLIKÁCIÓS LISTA/ PUBLICATIONS:

1. Rekasi Z., **Sule N.**, Csernus V., Mess B.
Adrenergic and peptidergic control of the regulation of cAMP efflux and Melatonin secretion from perfused rat pineal gland.
Endocrine 1998 Aug;9(1):89-96
impact factor: 1.6
2. Baer MR, Stewart CC, Dodge RK, Leget G, **Sule N**, Mrozek K, Schiffer CA, Powell BL, Kolitz JE, Moore JO, Stone RM, Davey FR, Carroll AJ, Larson RA, Bloomfield CD.
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Blood. 2001 Jun 1;97(11):3574-3580.
impact factor: 10.12
3. K. Szigeti, MD, **N. Sule**, MD, A. M. Adesina MD, PhD, G. M. Saifi, PhD, E. Bonilla, M. Hirano, MD and J. R. Lupski, MD, PhD
Increased Blood Brain Barrier Permeability Caused by Loss of Function of Thymidine Phosphorylase in Patients with MNGIE.
Ann Neurol. 2004 Dec;56(6):881-6.
impact factor: 7.71

4. **Norbert Sule**, M.D., Ulkem Yakupoglu, M.D., Steven S. Shen, M.D., Ph.D., Bhuvaneswari Krishnan, M.D., Guang Yang, M.D., Ph.D., Seth Lerner, M.D., and Luan D. Truong, M.D.

Calcium Oxalate Deposition in Renal Cell Carcinoma Associated with Acquired Cystic Kidney Disease. A Comprehensive Study.

Am J Surg Pathol. 2005 Apr;29(4):443-51.

impact factor: 4.5

5. Richard Kellermayer, M.D., Ph.D.; László Halvax, M.D., Ph.D.; Márta Czakó; Mohammad, Shahid; Dhillon S. Varinderpal, Ph.D.; Syed Akhtar Husain, Ph.D.; **Norbert Süle**, M.D.; Éva Gömöri, M.D.; Mariann Mammel; György Kosztolányi, M.D., Ph.D., D.Sci.

A novel frame shift mutation in the HMG-box of the SRY gene in a patient with complete 46,XY pure gonadal dysgenesis

Diagnostic Molecular Pathology 2005

Sep;14(3):159-163

impact factor: 2.1

6. István Buzogány, Fariborz Bagheri, **Norbert Süle**, Tamás Magyarlaki, Károly Kamár-Nagy, László Farkas, Gábor Pajor

Association between Carcinosarcoma and the Transplanted Kidney

Anticancer Research Jan-Feb 2006, volume 26, issue 1B, pp. 751-754

impact factor: 1.395

7. **Sule N**, Teszas A, Kalman E, Szigeti R, Miseta A, Kellermayer R.

Lithium Suppresses Epidermal SERCA2 and PMR1 Levels in the Rat.

Pathol Oncol Res. 2006;12(4):234-6. Epub 2006 Dec 25.

impact factor: 1.16

8. Komlosi K, Havasi V, Bene J, **Sule N**, Pajor L, Nicolai R, Benatti P, Calvani M, Melegh B.

Histopathologic abnormalities of the lymphoreticular tissues in organic cation transporter 2 deficiency: evidence for impaired B cell maturation.

J Pediatr. 2007 Jan; 150(1):109-111.e2.

impact factor: 4.272

9. Kinga Szigeti MD, PhD^{1,3}, Wojciech Wiszniewski MD, PhD¹, Gulam Mustafa Saifi PhD¹, Diane L. Sherman, PhD⁷, **Norbert Sule, MD⁴**, Adekunle M. Adesina, MD⁴, Pedro Mancias MD², Sozos Papasozomenos MD², Geoffrey Miller MD³, Laura Keppen MD⁵, Donna Daentl MD⁶, Peter J. Brophy PhD⁷ and James R. Lupski MD, PhD^{1,8,9}

Functional, histopathologic and natural history study of neuropathy associated with EGR2 mutations

Neurogenetics (accepted)

impact factor: 2.938

Összesített impact factor: 35.795

KONGRESSZUSOK JEGYZÉKE/ PRESENTATIONS

1. Rekasi Z., **Sule N.**, Csernus V., Mess B.:
Adrenergic and peptidergic interactions in the
regulation of cAMP efflux and Melatonin secretion
from perfused rat pineal
**Gordon Research Conferences, Pineal Cell
Biology, Ventura, California, February 4-9, 1996.**
2. Chizu Nakamoto, **Norbert Sule**, Steven Anderson, Larry
Suva, Michael Chorev, Michael Rosenblatt:
W008, Osteoprotegerin/Osteoclastogenesis Inhibitory
Factor mRNA is Down regulated by PTH and
Dexamethasone.
in Bone, Vol 23 (5) (Supplement) : S332
**2nd Joint Meeting of The American Society of
Bone and Mineral research and The International
Bone and Mineral Society, San Francisco, CA,
December 1-6,1998**
3. **N. Sule**, U. Yakupoglu , S. Shen , B. Krishnan and L.
Truong:
Calcium Oxalate Deposition in Renal Cell Carcinoma
Associated with Acquired Cystic Kidney Disease. A
Comprehensive Study
*Modern Pathology, Vol 17, Supplement 1:749,
January 2004*
**United States and Canadian Academy of
Pathology
93rd Annual Meeting, Vancouver, BC, Canada,
March 6-12, 2004**

4. K. Szigeti, **N. Sule**, A.M. Adenisa, G.M. Saifi, E. Bonilla, M. Hirano, J.R. Lupski

Increased Blood Brain Barrier Permeability Caused by Loss of Function of Thymidine Phosphorylase in Patients with MENGE (P01.022.)

American Academy of Neurology

56th Annual Meeting, San Francisco, CA, April 24-May 1, 2004

5. **N. Sule**, J. Lin, C. Leveque, D. Yawn

Successful Prevention Of Severe CNS Complication By Early Leukopheresis

World Apheresis Association

10th Congress hosted by the American Society for Apheresis 25th Annual Meeting, May 5-8, 2004, Miami, FL

6. **Süle N.**, Pajor G., Kneif M., Csala J., Holló T., Farkas L., Somogyi L., Pajor L

Automation in cytology laboratory: the role of fish combined with automated microscopic system in the detection of primary urothelial carcinoma in voided urine.

31st European Congress of Cytology, 2-5 October 2005

7. Pajor Gábor, Kneif Maria, Csala Judit, Farkas László, Somogyi László, Pajor László, **Sule Norbert**

Detection of primary urothelial carcinoma in voided urine specimen using four probe FISH assay combined with automated microscopic system, a prospective study

Virchow Archiv, Vol447, Number 2, August 2005, P-379

20th European Congress of Pathology, September 3-8, 2005 Paris, France

8. **Sule Norbert**, Yakupoglu Ulkem, Shen S. Steven, Krishnan Bhuvaneswari, Troung D. Luan

Comparative pathologic analysis of renal neoplasms developed in patients with ERDS and background renal changes

Virchow Archiv, Vol447, Number 2, August 2005, P-391

20th European Congress of Pathology, September 3-8, 2005 Paris, France

9. **Sule Norbert**, Powell Suzanne, Lupski R. James, Szigeti Kinga

Decreased thymidine phosphorylase _expression in brains affected by Alzheimer disease

Virchow Archiv, Vol447, Number 2, August 2005, P-985

20th European Congress of Pathology, September 3-8, 2005 Paris, France

10. PAJOR Gábor , KNEIF Mária , CSALA Judit , FARKAS László M.D. , SOMOGYI László M.D. , PAJOR László M.D., **SÜLE Norbert M.D.**

Primer Urotheliális Carcinoma ürített vizeletből történő vizsgálata FISH-el - manuális és automatizált kiértékelés

64th Congress of Hungarian Society of Pathology, September 22-24, Pécs, Hungary

REFERENCIÁK/ REFERENCES:

- Barama A, St-Louis G, Nicolet V, Hadjeres R, Daloze P. (2005). Renal cell carcinoma in kidney allografts: a case series from a single center. *Am J Transplant* 5,3015-8.
- Denton MD, Magee CC, Ovuworie C, Mauiyyedi S, Pascual M, Colvin RB, Cosimi AB, Tolkoff-Rubin N. (2002). Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. *Kidney Int* 61,2201-9.
- Doublet JD, Peraldi MN, Gattegno B, Thibault P, Sraer JD. (1997). Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. *J Urol* 158,42-4.
- Dry SM, Renshaw AA. (1998). Extensive calcium oxalate crystal deposition in papillary renal cell carcinoma: report of two cases. *Arch Pathol Lab Med* 122,260-1.
- Dunnill MS, Millard PR, Oliver D. (1977). Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis. *J Clin Pathol* 30,868-77.
- Eble JN, Sauter G, Epstein J, Sesterhenn I. 2004. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs: International Agency for Research on Cancer.
- Feldman JD, Jacobs SC. (1992). Late development of renal carcinoma in allograft kidney. *J Urol* 148,395-7.
- Gavrieli Y, Sherman Y, Ben-Sasson SA. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol* 119,493-501.

- Ghasemian SR, Guleria AS, Light JA, Sasaki TM. (1997). Multicentric renal cell carcinoma in a transplanted kidney. *Transplantation* 64,1205-6.
- Grantham JJ. (1991). Acquired cystic kidney disease. *Kidney Int* 40,143-52.
- Hatch M, Freel RW. (2003). Renal and intestinal handling of oxalate following oxalate loading in rats. *Am J Nephrol* 23,18-26.
- Hoppe B, Kemper MJ, Bokenkamp A, Portale AA, Cohn RA, Langman CB. (1999). Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. *Kidney Int* 56,268-74.
- Hughson MD, Buchwald D, Fox M. (1986). Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. *Arch Pathol Lab Med* 110,592-601.
- Hughson MD, Hennigar GR, McManus JF. (1980). Atypical cysts, acquired renal cystic disease, and renal cell tumors in end stage dialysis kidneys. *Lab Invest* 42,475-80.
- Hughson MD, Schmidt L, Zbar B, Daugherty S, Meloni AM, Silva FG, Sandberg AA. (1996). Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study. *J Am Soc Nephrol* 7,2461-8.
- Ikeda R, Tanaka T, Moriyama MT, Kawamura K, Miyazawa K, Suzuki K. (2002). Proliferative activity of renal cell carcinoma associated with acquired cystic disease of the kidney: comparison with typical renal cell carcinoma. *Hum Pathol* 33,230-5.

- Ishikawa I. (1991). Uremic acquired renal cystic disease. Natural history and complications. *Nephron* 58,257-67.
- Ishikawa I, Kovacs G. (1993). High incidence of papillary renal cell tumours in patients on chronic haemodialysis. *Histopathology* 22,135-9.
- Ishikawa I, Saito Y, Shikura N, Kitada H, Shinoda A, Suzuki S. (1990). Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. *Am J Kidney Dis* 16,452-8.
- Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. (2004). Cancer after kidney transplantation in the United States. *Am J Transplant* 4,905-13.
- Khurana KK, Truong LD, Verani RR. (1998). Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profiles in renal cell carcinoma associated with acquired cystic kidney disease: comparison with classic renal cell carcinoma. *Mod Pathol* 11,339-46.
- Kim MK, Kim S. (2002). Immunohistochemical profile of common epithelial neoplasms arising in the kidney. *Appl Immunohistochem Mol Morphol* 10,332-8.
- Kliem V, Kolditz M, Behrend M, Ehlerding G, Pichlmayr R, Koch KM, Brunkhorst R. (1997). Risk of renal cell carcinoma after kidney transplantation. *Clin Transplant* 11,255-8.
- Koul H, Ebisuno S, Renzulli L, Yanagawa M, Menon M, Scheid C. (1994). Polarized distribution of oxalate transport systems in LLC-PK1 cells, a line of renal epithelial cells. *Am J Physiol* 266,F266-74.
- Lieske JC, Spargo BH, Toback FG. (1992). Endocytosis of calcium oxalate crystals and proliferation of renal

- tubular epithelial cells in a patient with type 1 primary hyperoxaluria. *J Urol* 148,1517-9.
- MacDougall ML, Welling LW, Wiegmann TB. (1987). Renal adenocarcinoma and acquired cystic disease in chronic hemodialysis patients. *Am J Kidney Dis* 9,166-71.
- Matson MA, Cohen EP. (1990). Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. *Medicine (Baltimore)* 69,217-26.
- McGregor DK, Khurana KK, Cao C, Tsao CC, Ayala G, Krishnan B, Ro JY, Lechago J, Truong LD. (2001). Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'Renal Cell Carcinoma Marker'. *Am J Surg Pathol* 25,1485-92.
- Michaels EK, Ghosh L, Nakagawa Y, Netzer MF, Vidal P, Arsenault D, Ito H. (1998). Immunohistochemical localization of nephrocalcin, a kidney-specific glycoprotein, to renal cell carcinoma. *Urology* 52,920-4.
- Miller LR, Soffer O, Nassar VH, Kutner MH. (1989). Acquired renal cystic disease in end-stage renal disease: an autopsy study of 155 cases. *Am J Nephrol* 9,322-8.
- Morgan SH, Purkiss P, Watts RW, Mansell MA. (1987). Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria. *Nephron* 46,253-7.
- Neuzillet Y, Lay F, Luccioni A, Daniel L, Berland Y, Coulange C, Lechevallier E. (2005). De novo renal cell carcinoma of native kidney in renal transplant recipients. *Cancer* 103,251-7.

- Penn I. (1995). Primary kidney tumors before and after renal transplantation. *Transplantation* 59,480-5.
- Penn I. (1998). Occurrence of cancers in immunosuppressed organ transplant recipients. *Clin Transpl*147-58.
- Pfister C, Etienne I, Gobet F, Godin M, Grise P. (1999). Adenocarcinoma on renal allograft as a complication at 5 years. *Transplantation* 68,1608-10.
- Rioux-Leclercq NC, Epstein JI. (2003). Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney. *Arch Pathol Lab Med* 127,E89-92.
- Roupret M, Peraldi MN, Thaumat O, Chretien Y, Thiounn N, Dufour B, Kreis H, Mejean A. (2004). Renal cell carcinoma of the grafted kidney: how to improve screening and graft tracking. *Transplantation* 77,146-8.
- Salyer WR, Keren D. (1973). Oxalosis as a complication of chronic renal failure. *Kidney Int* 4,61-6.
- Samhan M, Al-Mousawi M, Donia F, Fathi T, Nasim J, Nampoory MR. (2005). Malignancy in renal recipients. *Transplant Proc* 37,3068-70.
- Scheid C, Koul H, Hill WA, Lubner-Narod J, Kennington L, Honeyman T, Jonassen J, Menon M. (1996). Oxalate toxicity in LLC-PK1 cells: role of free radicals. *Kidney Int* 49,413-9.
- Siebels M, Theodorakis J, Liedl B, Schneede P, Hofstetter A. (2000). Large de novo renal cell carcinoma in a 10-year-old transplanted kidney: successful organ-preserving therapy. *Transplantation* 69,677-9.
- Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K. (1997). Classification of renal cell carcinoma: Workgroup

No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). *Cancer* 80,987-9.

- Takebayashi S, Hidai H, Chiba T, Irisawa M, Matsubara S. (2000). Renal cell carcinoma in acquired cystic kidney disease: volume growth rate determined by helical computed tomography. *Am J Kidney Dis* 36,759-66.
- Thomson RB, Igarashi P, Biemesderfer D, Kim R, Abu-Alfa A, Soleimani M, Aronson PS. (1995). Isolation and cDNA cloning of Ksp-cadherin, a novel kidney-specific member of the cadherin multigene family. *J Biol Chem* 270,17594-601.
- Tickoo SK, dePeralta-Venturina MN, Salama M, Wang Y, Moch H, Amin MB. (2003). Spectrum of Epithelial Tumors in End Stage Renal Disease (ESRD): Emphasis on Histologic Patterns Distinct from Those in Sporadic Adult Renal Neoplasia. *Modern Pathology* 16,17BA.
- Truong LD, Krishnan B, Cao JT, Barrios R, Suki WN. (1995). Renal neoplasm in acquired cystic kidney disease. *Am J Kidney Dis* 26,1-12.
- Truong LD, Williams R, Ngo T, Cawood C, Chevez-Barrios P, Awalt HL, Brown RW, Younes M, Ro JY. (1998). Adult mesoblastic nephroma: expansion of the morphologic spectrum and review of literature. *Am J Surg Pathol* 22,827-39.
- Tyden G, Wernersson A, Sandberg J, Berg U. (2000). Development of renal cell carcinoma in living donor kidney grafts. *Transplantation* 70,1650-6.
- Worcester EM, Fellner SK, Nakagawa Y, Coe FL. (1994). Effect of renal transplantation on serum oxalate and urinary oxalate excretion. *Nephron* 67,414-8.